Brief: Cormedix Therapeutics Announces Positive Topline Results From Phase Iii Respect Trial

CorMedix

27/04/2026 13:33

April 27 (Reuters) - CorMedix Inc CRMD.O:

CORMEDIX THERAPEUTICS ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE III RESPECT TRIAL ASSESSING REZZAYO® FOR THE PROPHYLAXIS OF INVASIVE FUNGAL DISEASES IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION PATIENTS

CORMEDIX INC - STUDY SHOWS FAVORABLE BENEFIT FOR TOXICITY RELATED DISCONTINUATIONS AND DRUG-DRUG INTERACTIONS

CORMEDIX INC - REZAFUNGIN WELL TOLERATED WITH SAFETY PROFILE COMPARABLE TO STANDARD REGIMENS

CORMEDIX INC - COMPANIES ANTICIPATE PRE-NDA MEETING WITH FDA, TARGET SNDA SUBMISSION IN 2H26

CORMEDIX INC - RESPECT STUDY MEETS PRIMARY ENDPOINT FOR FUNGAL-FREE SURVIVAL AT DAY 90

Source text: ID:nGNX3Wwc1X

Further company coverage: CRMD.O

 ((Reuters.Briefs@thomsonreuters.com;))